Welcome to our dedicated page for Azenta SEC filings (Ticker: AZTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Azenta, Inc.'s SEC filings document operating results, material events, governance matters and acquisition agreements for a life sciences solutions company built around cold-chain sample management and multiomics services. Recent Form 8-K disclosures include quarterly results and financial-condition updates, leadership and board changes, and the material definitive agreement under which Azenta UK Ltd acquired UK Biocentre.
The company’s proxy and annual-meeting filings describe director elections, advisory executive-compensation votes, equity incentive plan amendments and auditor ratification. Together with material-event reports, these filings provide formal disclosure on Azenta’s governance structure, capital-related authorizations, transaction terms and recurring public-company reporting obligations.
Azenta, Inc. announced that its wholly owned subsidiary Azenta UK Ltd has acquired all shares of UK Biocentre Limited, a UK-based provider of sample management, storage and high-throughput processing services. The total consideration is GBP 20.5 million, net of cash and including up to GBP 1.8 million of milestone-based contingent payments.
UK Biocentre is expected to operate as Azenta’s European-wide hub for Sample Repository Services and will retain its name. The business generated approximately GBP 15.3 million in revenue over the twelve months ending fiscal September 30, 2025. Azenta expects the deal to be dilutive to its 2026 Adjusted EBITDA margin by about 35 basis points, but accretive to organic revenue growth and Adjusted EBITDA margin expansion targets for 2027 and 2028.
Azenta, Inc. director William L. Cornog filed an amended insider report to fix an administrative error in his equity holdings. The correction relates to a grant of 5,663 restricted stock units with a zero exercise price. After the correction, he is reported to beneficially own 9,703 derivative securities tied to Azenta common stock directly.
Azenta, Inc. director Tina S. Nova received an equity grant of 5,663 common shares under the company’s 2020 Equity Incentive Plan. The grant consisted of unrestricted shares, and no amount was paid upon grant. Following this award, she beneficially owns 15,772 Azenta common shares directly.
Azenta, Inc. reported an equity award to director William L. Cornog. On 02/05/2026, he received 5,663 restricted stock units (RSUs), each representing one share of Azenta common stock. The RSUs were granted at $0.00 under the company’s 2020 Equity Incentive Plan, with no cash paid at grant.
The units are fully vested upon grant, but settlement of the shares is deferred. Cornog elected to receive the underlying common stock at the later of his reaching age 65 or his separation from service with the company. After this grant, he beneficially owns 5,663 derivative securities directly.
Azenta director Martin Madaus received 5,663 restricted stock units on February 5, 2026 under the company’s 2020 Equity Incentive Plan. Each unit represents one share of Azenta common stock and was granted at no cost to him.
The units are fully vested on grant, but Madaus elected to defer settlement until the later of reaching age 65 or leaving the company. Following this award, he beneficially owns 9,703 derivative securities in the form of restricted stock units held directly.
Azenta director Dipal Doshi reported a stock grant from the company. On February 5, 2026, Doshi received 5,663 shares of Azenta common stock as a grant of unrestricted shares under the Company’s 2020 Equity Incentive Plan at a reported price of $27.85 per share. No cash was paid for this award, and Doshi now directly owns 9,703 common shares following the transaction.
Azenta, Inc. director Frank Casal reported receiving a grant of 7,243 shares of Azenta common stock on February 5, 2026 under the company’s 2020 Equity Incentive Plan. According to the filing, no cash was paid for this unrestricted share award.
After this grant, Casal beneficially owns 21,803 Azenta common shares, held directly. The transaction is reported as an acquisition of non-derivative securities and reflects routine equity-based compensation for a board member.
Azenta, Inc. director Erica McLaughlin received a grant of 5,663 shares of Azenta common stock on February 5, 2026. The shares are unrestricted and were granted under the company’s 2020 Equity Incentive Plan, with no cash paid for the grant. Following this award, she directly holds 22,521 Azenta common shares.
Azenta, Inc. director Robyn C. Davis received a grant of 5,663 restricted stock units on Azenta common stock on February 5, 2026. Each unit represents one share of common stock and was granted at a price of $0. The units are fully vested upon grant.
Davis elected to defer settlement of these units until the later of reaching age 65 or separating from service with the company. After this award, Davis beneficially owns 23,662 derivative securities in the form of restricted stock units, granted under Azenta’s 2020 Equity Incentive Plan.
Azenta, Inc. reported a net loss of $15.4M for the quarter ended December 31, 2025, compared with a loss of $11.0M a year earlier. Total revenue from continuing operations was broadly flat at $148.6M, with Sample Management Solutions at $81.4M and Multiomics at $67.2M.
Continuing operations generated a loss of $5.2M, while discontinued operations, mainly the B Medical Systems business, added a further loss of $10.2M. Azenta recorded a $9.7M loss on assets held for sale as it moves toward divesting B Medical.
Under a Share Purchase Agreement signed with Thelema S.À R.L., B Medical Systems is being sold for $63.0M. Thelema has paid a $9.0M deposit, with the remaining $54.0M due on or before March 31, 2026, subject to Thelema obtaining final financing; if this fails, Azenta retains $5.0M as a break-up fee.
Azenta ended the quarter with $336.6M in cash and cash equivalents, plus $228.9M in marketable securities, and total assets of $2.07B against liabilities of $359.6M. The company continues its 2024 restructuring program and has a new $250M share repurchase authorization through December 31, 2028, with no buybacks yet executed.